Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Tumor Susceptibility Gene 101 (TSG101) Peptide

TSG101 Reactivity: Human Host: Synthetic BP, WB
Catalog No. ABIN985664
  • Target See all TSG101 products
    TSG101 (Tumor Susceptibility Gene 101 (TSG101))
    Origin
    Human
    Source
    • 8
    Synthetic
    Application
    Blocking Peptide (BP), Western Blotting (WB)
    Characteristics
    This is a synthetic peptide designed for use in combination with anti-TSG101 antibody (Catalog #: ARP38773_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
    Purification
    Purified
  • Application Notes
    Each Investigator should determine their own optimal working dilution for specific applications.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
    Concentration
    1 mg/mL
    Buffer
    Final peptide concentration is 1 mg/mL in PBS.
    Handling Advice
    Avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target
    TSG101 (Tumor Susceptibility Gene 101 (TSG101))
    Background
    TSG101 belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. TSG101 contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. TSG101 may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of TSG101 appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in TSG101 gene occur in high frequency in breast cancer. The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.

    Alias Symbols: TSG10, VPS23

    Protein Interaction Partner: HGS,HGS,JEVgp1,PDCD6IP,PDCD6IP,TSG101,TSG101,VPS28,VPS28,VPS28,VPS37A,VPS37B,gag,AATF,AR,CDKN1A,CEP55,DAXX,DMAP1,DNMT1,EP300,GGA1,GGA3,GMCL1,HCK,HGS,KRT15,LRSAM1,MDM2,NR3C1,PDCD6IP,PPFIBP2,SNF8,TOM1L1,TP53,UBA52,VPS28,VPS36,VPS37A,VPS37B,VPS37C,VPS37D,AR,CDKN1A,CEP55,DMAP1,EP300,GGA3,HGS,ITSN1,KIF5A,KRT15,LRSAM1,MDM2,NR3C1,PPFIBP2,SCAMP3,SCNN1A,THRB,TP53,UBC,VPS28,VPS37A,VPS37B,VPS37C

    Protein Size: 390
    Molecular Weight
    44 kDa
    Gene ID
    7251
    NCBI Accession
    NM_006292, NP_006283
    UniProt
    Q99816
You are here:
Support